Market conditions are Mildly bullish in a Bear Market as of 2022-11-28. This means traders and investors should consider trading with a Neutral or Bullish bias by buying stocks and setting tight stops. The rank of the Bear Market is -16.70 which indicates the current market conditions are Extreme, Risk of a reversal is high. […]
Read MoreGritstone bio, Inc. (GRTS) Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder […]
Read MoreGrindrod Shipping Holdings Ltd. (GRIN) Grindrod Shipping Holdings Ltd., an international shipping company, owns, charters-in, and operates a fleet of dry bulk carriers and tankers worldwide. It operates a fleet of 23 owned dry bulk carriers and 8 long-term chartered-in dry bulk carriers that transport a range of bulk and breakbulk commodities, including ores, coal, […]
Read MoreBioNTech SE (BNTX) BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer. AmpliTech Group, Inc. (AMPG) […]
Read MoreAs recently as a few months ago, a lot of signs about the global pandemic seemed to suggest that the worst of the worst was over, and we could all finally begin to put COVID-19 concerns and commentary in the rear view. As contagious variants of the virus have emerged, however, it has become more […]
Read MoreBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial […]
Read More